Vistagen Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Shawn K. Singh and CFO Nick B. Tressler certified the Q2 2026 10-Q (quarter ended June 30, 2026) filed August 14, 2026, attesting to the accuracy of financial statements, effectiveness of disclosure controls, and absence of material misstatements. No specific operational, financial, or strategic changes are disclosed in these certification exhibits.
Why this rating
Boilerplate SOX 302/906 officer certifications. Routine quarterly filing requirement; no substantive business event disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.